دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Can PROMs improve racial equity in outcomes after prostatectomy?
Alexander P. Cole, Mara Koelker, Jonathan Makanjuola & Caroline M. MooreÂ
doi : 10.1038/s41585-022-00682-2
Volume 20 Issue 3, March 2023
Partial gland cryoablation for prostate cancer � where are we?
Wei Phin Tan, James S. Wysock & Herbert LeporÂ
GAH treatment improves mental health in transgender adolescents
Maria Chiara MasoneÂÂ
CMA mediates resistance to androgen inhibitors in prostate cancer
Maria Chiara MasoneÂÂ
A new text message-based platform for self-management of patients with IC/BPS
Maria Chiara MasoneÂÂ
Prostate cancer care for American Indians and Alaska Natives
Maria Chiara MasoneÂÂ
Pembrolizumab + axitinib beyond first-line therapy for mRCC
Tim ThomasÂÂ
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Alessandro Rizzo, Matteo Santoni & Francesco MassariÂ
doi : 10.1038/s41585-022-00676-0
The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of immunotherapy agents by regulatory agencies. However, objective and durable responses are still not observed in a large number of patients, and prognostic and predictive biomarkers for immunotherapy response are urgently needed.
Experimental in vitro, ex vivo and in vivo models in prostate cancer research
Verena Sailer, Gunhild von Amsberg, Stefan Duensing, Jutta Kirfel, Verena Lieb, Eric Metzger, Anne Offermann, Klaus Pantel, Roland Schuele, Helge Taubert, Sven Wach, Sven Perner, Stefan Werner & Achim AignerÂ
doi : 10.1038/s41585-022-00677-z
Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual disease progression.
Adjuvant therapy options in renal cell carcinoma � targeting the metastatic cascade
Kelly N. Fitzgerald, Robert J. Motzer & Chung-Han LeeÂ
doi : 10.1038/s41585-022-00666-2
Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is performed with curative intent. However, disease recurs in ~20% of patients. Treatment with adjuvant therapies is used after surgery with the intention of curing additional patients by disrupting the establishment, maturation or survival of micrometastases, processes collectively referred to as the metastatic cascade.
Author Correction: Can PROMs improve racial equity in outcomes after prostatectomy?
Alexander P. Cole, Mara Koelker, Jonathan Makanjuola & Caroline M. MooreÂ
